87 related articles for article (PubMed ID: 2297234)
1. [Effect of fosfomycin on cisplatin-induced renal tubular damage].
Itoh H; Watanabe A; Ooka T
Gan To Kagaku Ryoho; 1990 Jan; 17(1):147-50. PubMed ID: 2297234
[No Abstract] [Full Text] [Related]
2. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
3. [Experimental studies of the nephroprotective effect of fosfomycin].
Kreft B; Marre R; Schulz E; Sack K
Wien Med Wochenschr; 1987 Feb; 137(4):83-8. PubMed ID: 2954305
[TBL] [Abstract][Full Text] [Related]
4. Effect of cisplatin on plasma renin activity and serum aldosterone levels.
Kurt E; Manavoglu O; Dilek K; Orhan B; Evrensel T
Clin Nephrol; 1999 Dec; 52(6):397-8. PubMed ID: 10604651
[No Abstract] [Full Text] [Related]
5. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity.
Umeki S; Watanabe M; Yagi S; Soejima R
Am J Med Sci; 1988 Jan; 295(1):6-10. PubMed ID: 2827472
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of cisplatin-induced ototoxicity by fosfomycin.
Schweitzer VG; Dolan DF; Abrams GE; Davidson T; Snyder R
Laryngoscope; 1986 Sep; 96(9 Pt 1):948-58. PubMed ID: 3747696
[TBL] [Abstract][Full Text] [Related]
7. Tubular dysfunction after peritonectomy and chemohyperthermic treatment with cisplatin.
La Manna G; Virzì S; Deraco M; Capelli I; Accorsi A; Dalmastri V; Comai G; Bonomi S; Grassi A; Selva S; Feliciangeli G; Scolari M; Stefoni S
In Vivo; 2006; 20(6A):703-6. PubMed ID: 17203749
[TBL] [Abstract][Full Text] [Related]
8. [Protective effect of urinastatin on cisplatin-induced cytotoxicity in the renal tubules].
Kawasaki K; Shiba R
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2273-6. PubMed ID: 2241193
[No Abstract] [Full Text] [Related]
9. Measurement of urinary beta 2-microglobulin in the detection of cisplatin nephrotoxicity.
Cohen AI; Harberg J; Citrin DL
Cancer Treat Rep; 1981; 65(11-12):1083-5. PubMed ID: 6170429
[No Abstract] [Full Text] [Related]
10. [Influence of a fosfomycin combination on the anti-tumor effect of CDDP].
Sagara N; Nakano K; Aizawa M; Hara S; Inufusa H; Mori N; Kurooka K; Haeno Y; Yasutomi M
Gan To Kagaku Ryoho; 1988 Jan; 15(1):97-100. PubMed ID: 3337531
[TBL] [Abstract][Full Text] [Related]
11. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
12. [Toxicity of cisplatin administered with hydration of 1-hour duration and forced diuresis].
Lopez M; Papaldo P; Perno CF; Di Lauro L; Barduagni A
Clin Ter; 1983 Nov; 107(3):207-13. PubMed ID: 6686503
[No Abstract] [Full Text] [Related]
13. [Combination chemotherapy with mitomycin C, adriamycin and cisplatin (MAP) in advanced adenocarcinoma of the lung: clinical effect and renal toxicity].
Fujii M; Kiura K; Okabe K; Toki H
Gan To Kagaku Ryoho; 1987 Jan; 14(1):105-8. PubMed ID: 3099647
[TBL] [Abstract][Full Text] [Related]
14. [Preventive effect of fosfomycin on the renal toxicity of cisplatin].
Kurebe M; Niizato T; Sanda M; Sasaki H; Hayasaka H
Jpn J Antibiot; 1985 Jan; 38(1):62-8. PubMed ID: 3157808
[TBL] [Abstract][Full Text] [Related]
15. [Early phase II study of FK352 in cisplatin-induced nephropathy. Niigata Prefecture FK352 Study Group].
Yoshizawa H; Suzuki E; Arakawa M
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2085-94. PubMed ID: 9838911
[TBL] [Abstract][Full Text] [Related]
16. Reduction of cisplatin ototoxicity by fosfomycin in animal model.
Ohtani I; Ohtsuki K; Aikawa T; Anzai T; Ouchi J; Saito T
ORL J Otorhinolaryngol Relat Spec; 1985; 47(5):229-35. PubMed ID: 4047624
[TBL] [Abstract][Full Text] [Related]
17. Sodium-wasting nephropathy caused by cisplatin in esophageal cancer.
Abdelghani L; Modha K; Albaddawi E; Subramanian S
J Support Oncol; 2008; 6(7):305-6. PubMed ID: 18847072
[No Abstract] [Full Text] [Related]
18. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
Saito M; Masaki T; Kato H; Numasaka K
Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of renal toxicity of cisplatin by administration of bismuth subnitrate].
Hamada T; Nishiwaki Y; Kodama T; Hayashibe A; Nukariya N; Sasaki H; Morikawa T; Hirosawa T; Matsuyama T
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3587-93. PubMed ID: 2554815
[TBL] [Abstract][Full Text] [Related]
20. [Kidney function in oncologic patients after cisplastin chemotherapy].
Hozhenko AI; Moskalenko OM; Sirman VM; ZhiZhnievs'ka OO; Storozhenko SA
Fiziol Zh (1994); 2012; 58(3):72-6. PubMed ID: 22946315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
